Alnylam Pharmaceuticals, Inc. $ALNY Shares Acquired by Allstate Corp

Allstate Corp grew its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 115.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 9,829 shares of the biopharmaceutical company’s stock after purchasing an additional 5,258 shares during the quarter. Allstate Corp’s holdings in Alnylam Pharmaceuticals were worth $3,909,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Root Financial Partners LLC purchased a new position in shares of Alnylam Pharmaceuticals during the third quarter valued at approximately $25,000. Caitong International Asset Management Co. Ltd purchased a new position in shares of Alnylam Pharmaceuticals during the third quarter valued at approximately $29,000. Ameriflex Group Inc. purchased a new position in shares of Alnylam Pharmaceuticals during the third quarter valued at approximately $32,000. Aster Capital Management DIFC Ltd purchased a new position in shares of Alnylam Pharmaceuticals during the third quarter valued at approximately $36,000. Finally, Newbridge Financial Services Group Inc. purchased a new position in Alnylam Pharmaceuticals during the third quarter worth approximately $39,000. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, insider Melissa Mclaughlin sold 2,286 shares of Alnylam Pharmaceuticals stock in a transaction on Monday, April 6th. The shares were sold at an average price of $330.42, for a total transaction of $755,340.12. Following the sale, the insider owned 9,443 shares of the company’s stock, valued at $3,120,156.06. The trade was a 19.49% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Tolga Tanguler sold 1,598 shares of Alnylam Pharmaceuticals stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $327.65, for a total transaction of $523,584.70. Following the sale, the executive vice president directly owned 36,606 shares in the company, valued at $11,993,955.90. This trade represents a 4.18% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 21,255 shares of company stock worth $6,930,337 over the last three months. 0.86% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on ALNY shares. Citigroup started coverage on shares of Alnylam Pharmaceuticals in a report on Tuesday, May 19th. They issued a “buy” rating and a $380.00 price target on the stock. Jefferies Financial Group reiterated a “hold” rating and issued a $330.00 price target (down from $522.00) on shares of Alnylam Pharmaceuticals in a report on Monday, March 16th. Wells Fargo & Company lifted their price target on shares of Alnylam Pharmaceuticals from $376.00 to $377.00 and gave the company an “equal weight” rating in a report on Friday, May 1st. Canaccord Genuity Group lifted their price target on shares of Alnylam Pharmaceuticals from $415.00 to $429.00 and gave the company a “buy” rating in a report on Tuesday, February 17th. Finally, Needham & Company LLC decreased their price target on shares of Alnylam Pharmaceuticals from $529.00 to $510.00 and set a “buy” rating on the stock in a report on Thursday, February 12th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $463.13.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY stock opened at $295.63 on Thursday. The company’s fifty day simple moving average is $309.94 and its 200-day simple moving average is $356.07. Alnylam Pharmaceuticals, Inc. has a 52 week low of $284.28 and a 52 week high of $495.55. The company has a current ratio of 3.13, a quick ratio of 3.06 and a debt-to-equity ratio of 0.94. The company has a market cap of $39.47 billion, a PE ratio of 80.77 and a beta of 0.31.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 EPS for the quarter, beating analysts’ consensus estimates of $0.87 by $1.12. Alnylam Pharmaceuticals had a net margin of 11.72% and a return on equity of 85.76%. The business had revenue of $1.17 billion for the quarter, compared to the consensus estimate of $1.12 billion. During the same quarter last year, the firm posted ($0.44) EPS. The business’s revenue for the quarter was up 96.4% compared to the same quarter last year. As a group, equities research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post 7.36 EPS for the current year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.